1.60
0.00%
+0.00
After Hours:
1.60
Compass Therapeutics Inc stock is currently priced at $1.60, with a 24-hour trading volume of 177.58K.
It has seen a +0.00% increased in the last 24 hours and a +4.58% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.59 pivot point. If it approaches the $1.62 resistance level, significant changes may occur.
Previous Close:
$1.60
Open:
$1.65
24h Volume:
177.58K
Market Cap:
$220.14M
Revenue:
-
Net Income/Loss:
$-42.49M
P/E Ratio:
-4.3243
EPS:
-0.37
Net Cash Flow:
$-40.65M
1W Performance:
+0.00%
1M Performance:
+4.58%
6M Performance:
+0.63%
1Y Performance:
-50.62%
Compass Therapeutics Inc Stock (CMPX) Company Profile
Name
Compass Therapeutics Inc
Sector
Industry
Phone
617 500 8099
Address
80 Guest Street, Suite 601, Boston
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-31-23 | Initiated | Jefferies | Buy |
Jan-27-23 | Initiated | Stifel | Buy |
May-23-22 | Resumed | H.C. Wainwright | Buy |
Mar-15-22 | Initiated | Ladenburg Thalmann | Buy |
Jan-19-22 | Initiated | B. Riley Securities | Buy |
Dec-22-21 | Initiated | Raymond James | Outperform |
Dec-20-21 | Initiated | SVB Leerink | Outperform |
Dec-15-21 | Initiated | Wedbush | Outperform |
View All
Compass Therapeutics Inc Stock (CMPX) Latest News
Compass Therapeutics, Inc. (NASDAQ:CMPX) Forecasted to Post Q2 2024 Earnings of ($0.11) Per Share - Defense World
Defense World
Q2 2024 Earnings Forecast for Compass Therapeutics, Inc. (NASDAQ:CMPX) Issued By HC Wainwright - Defense World
Defense World
Kier Group (LON:KIE) Rating Reiterated by Berenberg Bank - Defense World
Defense World
HC Wainwright Equities Analysts Boost Earnings Estimates for Compass Therapeutics, Inc. (NASDAQ:CMPX) - MarketBeat
MarketBeat
Analytical Lens: Exploring Compass Therapeutics Inc (CMPX)'s Financial Story Through Ratios – DWinneX - The Dwinnex
The Dwinnex
Compass Therapeutics Inc (CMPX) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
The InvestChronicle
Compass Therapeutics Inc Stock (CMPX) Financials Data
Compass Therapeutics Inc (CMPX) Net Income 2024
CMPX net income (TTM) was -$42.49 million for the quarter ending December 31, 2023, a -8.33% decrease year-over-year.
Compass Therapeutics Inc (CMPX) Cash Flow 2024
CMPX recorded a free cash flow (TTM) of -$40.65 million for the quarter ending December 31, 2023, a -18.38% decrease year-over-year.
Compass Therapeutics Inc (CMPX) Earnings per Share 2024
CMPX earnings per share (TTM) was -$0.33 for the quarter ending December 31, 2023, a +10.81% growth year-over-year.
About Compass Therapeutics Inc
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Its scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company's pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment; and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Cap:
|
Volume (24h):